A detailed history of Ameriprise Financial Inc transactions in Olema Pharmaceuticals, Inc. stock. As of the latest transaction made, Ameriprise Financial Inc holds 463,124 shares of OLMA stock, worth $4.68 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
463,124
Previous 441,066 5.0%
Holding current value
$4.68 Million
Previous $4.77 Million 15.86%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.41 - $16.46 $229,623 - $363,074
22,058 Added 5.0%
463,124 $5.53 Million
Q2 2024

Aug 14, 2024

BUY
$8.73 - $13.99 $1.12 Million - $1.79 Million
127,820 Added 40.8%
441,066 $4.77 Million
Q1 2024

May 15, 2024

BUY
$10.95 - $16.62 $579,134 - $879,015
52,889 Added 20.31%
313,246 $3.55 Million
Q4 2023

Feb 14, 2024

SELL
$10.53 - $17.14 $936,306 - $1.52 Million
-88,918 Reduced 25.46%
260,357 $3.65 Million
Q3 2023

Nov 14, 2023

BUY
$8.19 - $12.98 $982,062 - $1.56 Million
119,910 Added 52.28%
349,275 $4.31 Million
Q2 2023

Aug 14, 2023

BUY
$3.22 - $9.65 $738,555 - $2.21 Million
229,365 New
229,365 $2.07 Million
Q4 2021

Feb 14, 2022

SELL
$8.75 - $30.71 $1.85 Million - $6.48 Million
-210,926 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$22.96 - $30.13 $7.14 Million - $9.37 Million
-311,148 Reduced 59.6%
210,926 $5.82 Million
Q2 2021

Aug 16, 2021

BUY
$21.15 - $36.14 $1.21 Million - $2.06 Million
57,060 Added 12.27%
522,074 $14.6 Million
Q1 2021

May 17, 2021

BUY
$27.81 - $53.64 $2.74 Million - $5.28 Million
98,412 Added 26.84%
465,014 $15.4 Million
Q4 2020

Feb 12, 2021

BUY
$37.09 - $54.5 $13.6 Million - $20 Million
366,602 New
366,602 $17.6 Million

Others Institutions Holding OLMA

About Olema Pharmaceuticals, Inc.


  • Ticker OLMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,419,600
  • Market Cap $408M
  • Description
  • Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...
More about OLMA
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.